Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 2/20 | 0.36 |
| ▸ | DAGLA | Q9Y4D2 | 4/20 | 0.35 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6194843 | 0.91 | ALDH1A1 (0.35) | DAGLAABHD6 | |
| SCHEMBL6192809 | 0.89 | ATM (0.37) | DAGLAABHD6ATMHTR2C | |
| SCHEMBL6196153 | 0.87 | KDM4E (0.36) | DAGLAABHD6ATM | |
| SCHEMBL6193158 | 0.79 | TSHR (0.45) | — | |
| SCHEMBL6194492 | 0.79 | CCR5 (0.41) | ATM | |
| SCHEMBL6194530 | 0.78 | HTR2C (0.44) | HTR2C | |
| SCHEMBL6193124 | 0.77 | GRIN2B (0.41) | — | |
| SCHEMBL6193429 | 0.77 | RIPK1 (0.36) | — | |
| SCHEMBL6194416 | 0.77 | CNR1 (0.36) | — | |
| SCHEMBL6192757 | 0.76 | PSEN1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432701-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI IRELAND LTD (IE) | 2005-12-21 | — | — | EP | claimed |
| EP-1432701-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 2004-06-30 | — | — | EP | claimed |
| US-20030181446-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-09-25 | — | — | US | claimed |
| WO-2003031436-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. (CH) | 2003-04-17 | — | — | WO | claimed |
| EP-1432701-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI IRELAND LTD (IE) | 2005-12-21 | — | — | EP | disclosed |
| EP-1432701-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 2004-06-30 | — | — | EP | disclosed |
| US-20030181446-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-09-25 | — | — | US | disclosed |
| US-20030162777-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-08-28 | — | — | US | disclosed |
| WO-2003031436-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. (CH) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162777-A1 | Novel N-acylated heterocycles | HTR1A, HTR1D, HTR1E | CCR3 2412/4885DAGLA 3959/4885ABHD6 3584/4885 |
| US-20030181446-A1 | Novel N-acylated heterocycles | HTR1A, HTR1E, HTR2C | CCR3 2865/4885DAGLA 2684/4885ABHD6 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.